Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07165132 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 9 → 14 locations Eligibility criteria expanded, about 15 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 15 words
  2. Trial sites expanded: 4 → 9 locationsv3
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 4 · Completion date: Oct 2032 to Apr 2033 · Start date changed from estimate of Oct 2025 to Dec 3, 2025 · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 4
    • Completion date: Oct 2032 to Apr 2033
    • Start date changed from estimate of Oct 2025 to Dec 3, 2025
    • Eligibility criteria expanded, about 94 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.
Trial Details
NCT Number NCT07165132
Lead Sponsor RayzeBio, Inc.
Conditions GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET, Solid Tumor +1 more
Enrollment 104 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov